Converting tumor-associated macrophages (TAMs) from the M2 to the M1 phenotype is considered an effective strategy for
cancer therapy.
TRAF3 is known to regulate NF-κB signaling. However, the role of
TRAF3 in TAM polarization has not yet been completely elucidated. Here, we found that ablation of
TRAF3 increased M1 markers, iNOS, FGR and SLC4A7, while down-regulated M2 markers, CD206, CD36 and ABCC3, expression levels in macrophages. Moreover,
TRAF3 deficiency enhanced LPS-induced M1 and abolished IL-4-induced macrophage polarization. Next, quantitative ubiquitomics assays demonstrated that among the quantitative 7618 ubiquitination modification sites on 2598
proteins, ubiquitination modification of
IL-4 responding
proteins was the most prominently reduced according to enrichment analysis. STAT6, a key factor of
IL-4 responding
protein, K450 and K129 residue ubiquitination levels were dramatically decreased in TRAF3-deficient macrophages. Ubiquitination assay and
luciferase assay demonstrated that
TRAF3 promotes STAT6 ubiquitination and transcriptional activity. Site mutation analysis revealed STAT6 K450 site ubiquitination played a vital role in TRAF3-mediated STAT6 activation. Finally,
B16 melanoma mouse model demonstrated that myeloid
TRAF3 deficiency suppressed
tumor growth and lung
metastasis in vivo. Taken together,
TRAF3 plays a vital role in M2 polarization via regulating STAT6 K450 ubiquitination in macrophages.